RESUMEN
The recently-identified Wiskott-Aldrich syndrome protein gene (WASP) is responsible for the Wiskott-Aldrich X-linked immunodeficiency as well as for isolated X-linked thrombocytopenia (XLT). To characterize the regulatory sequences of the WASP gene, we have isolated, sequenced and functionally analyzed a 1.6-Kb DNA fragment upstream of the WASP coding sequence. Transfection experiments showed that this fragment is capable of directing efficient expression of the reporter chloramphenicol acetyltransferase (CAT) gene in all human hematopoietic cell lines tested. Progressive 5' deletions showed that the minimal sequence required for hematopoietic-specific expression consists of 137 bp upstream of the transcription start site. This contains potential binding sites for several hematopoietic transcription factors and, in particular, two Ets-1 consensus that proved able to specifically bind to proteins present in nuclear extracts of Jurkat cells. Overexpression of Ets-1 in HeLa resulted in transactivation of the CAT reporter gene under the control of WASP regulatory sequences. Disruption of the Ets-binding sequences by side-directed mutagenesis abolished CAT expression in Jurkat cells, indicating that transcription factors of the Ets family play a key role in the control of WASP transcription.
Asunto(s)
Regulación de la Expresión Génica , Células Madre Hematopoyéticas/fisiología , Proteínas/genética , Secuencia de Bases , Células HeLa , Humanos , Células Jurkat , Datos de Secuencia Molecular , Biosíntesis de Proteínas , Transfección , Síndrome de Wiskott-Aldrich/genética , Proteína del Síndrome de Wiskott-Aldrich , Cromosoma XRESUMEN
We previously reported that T lymphocytes of atopic patients displayed a defect in CD2- and CD3-mediated pathways of cell activation; that defect relied on impairment of interleukin 2 (IL-2) production (Romano, M. F., Valerio, G., Turco, M. C., Spadaro, G., Venuta, S., and Formisono, S., Cell. Immunol. 139, 91, 1992). We have subsequently analyzed T cell response to anti-CD2, -CD3, or -CD28 monoclonal antibodies (mAb) in 40 atopic individuals, including patients subjected to immunotherapy. In the latter group T cell response to anti-CD2 mAbs was normal, while IL-2 production and proliferative response in T lymphocytes stimulated via CD3 was still impaired. Costimulation with anti-CD28 mAb rescued both IL-2 production and proliferative response in all tested patients. Response to CD28-mediated stimulation was more pronounced in atopic than that in normal individuals. Our results indicated that CD28 had a major role in T cell proliferation of atopic patients and provided a model for analyzing CD3/CD28 interactions in regulation of IL-2 gene expression.
Asunto(s)
Antígenos CD/inmunología , Antígenos de Diferenciación de Linfocitos T/inmunología , Hipersensibilidad/inmunología , Interleucina-2/biosíntesis , Activación de Linfocitos , Linfocitos T/inmunología , Adulto , Antígenos CD2 , Antígenos CD28 , Complejo CD3/inmunología , Humanos , Hipersensibilidad/terapia , Inmunoterapia , Persona de Mediana Edad , Receptores Inmunológicos/inmunologíaRESUMEN
Human T lymphocyte proliferative response induced via CD28 molecule is analyzed. An anti CD28 MoAb, CLB-CD28/1, induces the proliferation of human peripheral blood mononuclear cells in the absence of other stimuli, indicating that CD28 molecule can directly mediate a mitogenic signal in this system. The mitogenic activity of MoAb CLB-CD28/1 on PBMC does not require MoAb interaction with monocyte Fc receptors, since F(ab')2 fragments from the MoAb are mitogenic to the same extent as whole IgG. Nevertheless, the activity depends on the presence of accessory cells, since purified T lymphocytes require addition of irradiated monocytes and interleukin 2 to proliferate when incubated with MoAb CLB-CD28/1. On the other hand, MoAb CLB-CD28/1 induces response to IL-2 in thymocytes in the absence of accessory cells. Cooperation of MoAb CLB-CD28/1 with three other MoAbs, recognizing CD3, CD5 and HLA Class I antigens, respectively, induces Tac antigen expression and IL-2 responsiveness in purified T lymphocytes. This effect is obtained without cross-linking of the MoAb. It does not rely on a physical association between CD28 and CD3, CD5 or HLA Class I molecules, as demonstrated by co-modulation experiments. These data indicate that expression of IL-2 receptor on T lymphocytes can result from interaction of multiple activation pathways and that some of them, such as those mediated by CD5 and HLA Class I antigens, previously reported to serve as modulatory circuits, can instead act as essential elements in the onset of T lymphocyte proliferation.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Antígenos de Diferenciación de Linfocitos T/inmunología , Leucocitos Mononucleares/citología , Activación de Linfocitos/efectos de los fármacos , Linfocitos T/citología , Anticuerpos Monoclonales/inmunología , Antígenos de Diferenciación/inmunología , Antígenos CD28 , Complejo CD3 , Antígenos CD5 , División Celular/efectos de los fármacos , Antígenos de Histocompatibilidad Clase I/inmunología , Humanos , Fragmentos Fab de Inmunoglobulinas/inmunología , Interleucinas/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Monocitos/fisiología , Receptores de Antígenos de Linfocitos T/inmunología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Timo/citología , Timo/efectos de los fármacosRESUMEN
The mAb 131 to a determinant preferentially expressed on the gene products of the HLA-A locus, the mAb Q6/64 and 4E to determinants preferentially expressed on the gene products of the HLA-B locus, the anti-HLA-A2,A28 mAb CR11-351, HO-2, HO-3, HO-4, and KS1, and the anti-HLA-B7 cross-reacting group mAb KS4 enhanced proliferation of T cells in most, if not all, the PBMC preparations stimulated with the anti-CD2 mAb 9-1 + 9.6. The mAb CR10-215, W6/32, and 6/31 to distinct monomorphic determinants of HLA class I antigens enhanced CD2-induced T cell proliferation in at most 30% of the PBMC preparations tested. The anti human beta 2-microglobulin (beta 2-mu) mAb NAMB-1 displayed no detectable effect on the proliferation of T cells stimulated with the mAb 9-1 + 9.6. The enhancing effect of anti-HLA class I mAb is specific, is dose dependent, is not abrogated by the addition of exogenous IL-1 and IL-2 to the cultures, and reflects the interaction of anti-HLA class I mAb with T cells. Enhancement of CD2 mediated proliferation of T cells is not a unique property of anti-HLA class I mAb, since the anti-HLA class II mAb Q5/6 and Q5/13 also had a similar effect. Analysis of the kinetics of the enhancing effect of anti-HLA class I mAb suggests that they modulate an early event of T cell activation and may affect the interaction of T cells with mAb 9-1. Phenotyping of T lymphocytes activated by mAb 9-1 + 9.6 in the presence of anti-HLA class I mAb suggests that the enhancing effect of anti-HLA class I mAb may reflect the recruitment of a higher percentage of T cells. The present study has shown for the first time that certain, but not all, the determinants of the HLA class I molecular complex are involved in the proliferation of T cells stimulated with the anti-CD2 mAb 9-1 + 9.6. Furthermore, the inhibitory effect of mAb CR11-351, KS1, Q6/64, and W6/32 on the proliferation of T cells stimulated with mAb OKT3 or with mAb BMA 031 indicates that the same determinants of HLA class I antigens play a differential regulatory role in T cell proliferation induced via the CD2 and CD3 pathway.
Asunto(s)
Adyuvantes Inmunológicos/fisiología , Anticuerpos Monoclonales/fisiología , Antígenos de Diferenciación de Linfocitos T/inmunología , Antígenos HLA/inmunología , Activación de Linfocitos , Linfocitos T/inmunología , Medios de Cultivo/análisis , Antígenos HLA-D/inmunología , Humanos , Fragmentos Fab de Inmunoglobulinas/fisiología , Interleucina-2/análisis , Cinética , Receptores de Interleucina-2/análisis , Receptores de Transferrina/análisisRESUMEN
Monoclonal antibodies (mAb) to monomorphic and polymorphic determinants on the heavy chain of histocompatibility leukocyte antigen (HLA) class I antigens inhibit mAb OKT3-induced T cell proliferation, whereas the anti-beta 2-microglobulin mAb NAMB-1 does not affect it. The inhibitory effect of anti-HLA class I mAb is specific, is not an Fc-mediated phenomenon, does not require accessory cells, and does not involve early stages of T cell activation. Distinct determinants of HLA class I antigens regulate T cell proliferation by different mechanisms, because the anti-HLA-A2, A28 mAb CR11-351, and the mAb W6/32 to a framework determinant of HLA class I antigens block interleukin 2 (IL-2) secretion and IL-2 receptor expression, whereas the mAb CR10-215 to a monomorphic determinant blocks only IL-2 receptor expression. The mAb CR10-215 and W6/32 induced a 50% of maximal inhibition of T cell proliferation, when added after 27 and 12 hr, respectively, of incubation of peripheral blood mononuclear cells with mAb OKT3. On the other hand, the mAb CR11-351 inhibited T cell proliferation even when added after 38 hr of incubation of peripheral blood mononuclear cells with mAb OKT3 and was the only one to inhibit proliferation of cycling T lymphocytes. It is suggested that HLA class I antigens regulate T cell proliferation by interacting with cell-surface molecules involved in T cell activation. The differential inhibitory activity of the anti-HLA class I monoclonal antibodies tested may reflect the different ability of the corresponding determinants to interact with activation molecules.
Asunto(s)
Antígenos de Diferenciación de Linfocitos T/inmunología , Antígenos HLA/inmunología , Activación de Linfocitos , Linfocitos T/inmunología , Anticuerpos Monoclonales/inmunología , Células Presentadoras de Antígenos/inmunología , Epítopos , Interleucina-2/metabolismo , Isoanticuerpos/inmunología , Polimorfismo Genético , Proteínas Proto-Oncogénicas/genética , ARN Mensajero/genética , Receptores Fc/fisiologíaRESUMEN
The prevalence of diabetes in subjects aged 18 yr and over was evaluated in a rural community of Southern Italy (Sanza). Among the 1,154 participants examined by using a 75 g oral glucose load according to the recent WHO diagnostic criteria, the diabetes prevalence was 6.6% in men and 6.8% in women; impaired glucose tolerance occurred in 5.1% of men and 7.9% of women. The frequency of positive family history of diabetes was no higher in subjects with diabetes and impaired glucose tolerance, than in controls. Obesity was clearly related to diabetes (p less than 0.05 in men and p less than 0.01 in women 40 yr old and over). The level of physical activity was significantly lower in subjects with diabetes than in normal subjects. The results suggest that a remarkable reduction in physical activity, along with an increased caloric intake, may have importance in determining the prevalence and time of appearance of non-insulin-dependent diabetes.